Based on the recommendations of the European Heart Society and the results of clinical and register studies, the article highlights the complex issues that arise when prescribing antiplatelet therapy in patients with acute coronary syndrome, including with concomitant atrial fibrillation (AF); the promising strategies for managing the risk of ischemic and hemorrhagic events are described. Also a clinical case of a patient with acute coronary syndrome and AF is presented, illustrating the objective complexity of correct selection of antiplatelet therapy in such patients
Numerous clinical trials have established the value of antiplatelet therapies for acute coronary syn...
The article presents modern approaches to choosing a P2Y12 inhibitor as part of combined antithrombo...
AbstractThe treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolu...
The review article on the basis of recommendations of the European Society of Cardiology and results...
Coronary heart disease (CHD) is the most common cardiovascular disease, while atrial fibrillation (A...
If atrial fibrillation (AF) and acute coronary syndrome (ACS) coexist, they should be treated with ...
PURPOSE: Atrial fibrillation (AF) and coronary heart disease (CHD) commonly occur together. Previous...
Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatel...
Dual antiplatelet therapy is currently recommended for all patients with acute coronary syn-dromes, ...
In the review based on existing clinical recommendations and guidelines of the European cardiology s...
Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 receptor antagonist, is the stan...
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
The aim was to study the possible protective effect of drug therapy regarding the development of AF ...
This article is devoted to the problem of combined antithrombotic therapy in patients with atrial fi...
Several therapeutic approaches have been developed to improve the outcome among patients with acute ...
Numerous clinical trials have established the value of antiplatelet therapies for acute coronary syn...
The article presents modern approaches to choosing a P2Y12 inhibitor as part of combined antithrombo...
AbstractThe treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolu...
The review article on the basis of recommendations of the European Society of Cardiology and results...
Coronary heart disease (CHD) is the most common cardiovascular disease, while atrial fibrillation (A...
If atrial fibrillation (AF) and acute coronary syndrome (ACS) coexist, they should be treated with ...
PURPOSE: Atrial fibrillation (AF) and coronary heart disease (CHD) commonly occur together. Previous...
Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatel...
Dual antiplatelet therapy is currently recommended for all patients with acute coronary syn-dromes, ...
In the review based on existing clinical recommendations and guidelines of the European cardiology s...
Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 receptor antagonist, is the stan...
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
The aim was to study the possible protective effect of drug therapy regarding the development of AF ...
This article is devoted to the problem of combined antithrombotic therapy in patients with atrial fi...
Several therapeutic approaches have been developed to improve the outcome among patients with acute ...
Numerous clinical trials have established the value of antiplatelet therapies for acute coronary syn...
The article presents modern approaches to choosing a P2Y12 inhibitor as part of combined antithrombo...
AbstractThe treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolu...